| Hidehiro Takei, MD | |
|
6411 Fannin Street, Houston, TX 77030-1501 | |
| (713) 704-4000 | |
| (713) 704-2658 |
| Full Name | Hidehiro Takei |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 34 Years |
| Location | 6411 Fannin Street, Houston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023104528 | NPI | - | NPPES |
| 184566102 | Medicaid | TX | |
| 184566101 | Medicaid | TX |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Hermann - Texas Medical Center | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The University Of Texas Health Science Center At Houston | 8224936836 | 45 |
News Archive
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
Findings from a large-scale clinical trial testing a new palliative care model have shown to be lower cost, viewed positively by patients and their carers while showing no difference in patient-reported outcomes when compared with standard care.
The bipartisan treatment the FDA user fee bill has enjoyed did not fall like manna from heaven. It came at the insistence of the pharmaceutical and medical device industries, the FDA and legislators on both sides of the aisle who agreed early on they would get a deal done. And then actually did it.
The Cancer Council Australia cautioned that the vaccine was not a substitute for the Pap screen and that all women aged 18-69 should continue regular two year screening.
The Food and Drug Administration's mandatory added sugar labeling policy for packaged foods and beverages, set to take effect between 2020 and 2021, could be a cost-effective way to generate important health gains and cost-savings for both the healthcare system and society in the U.S., according to a new modeling study led by researchers from the Friedman School of Nutrition Science and Policy at Tufts University and the University of Liverpool.
› Verified 3 days ago
| Entity Name | The University Of Texas Health Science Center At Houston |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831142751 PECOS PAC ID: 8224936836 Enrollment ID: O20031220000059 |
News Archive
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
Findings from a large-scale clinical trial testing a new palliative care model have shown to be lower cost, viewed positively by patients and their carers while showing no difference in patient-reported outcomes when compared with standard care.
The bipartisan treatment the FDA user fee bill has enjoyed did not fall like manna from heaven. It came at the insistence of the pharmaceutical and medical device industries, the FDA and legislators on both sides of the aisle who agreed early on they would get a deal done. And then actually did it.
The Cancer Council Australia cautioned that the vaccine was not a substitute for the Pap screen and that all women aged 18-69 should continue regular two year screening.
The Food and Drug Administration's mandatory added sugar labeling policy for packaged foods and beverages, set to take effect between 2020 and 2021, could be a cost-effective way to generate important health gains and cost-savings for both the healthcare system and society in the U.S., according to a new modeling study led by researchers from the Friedman School of Nutrition Science and Policy at Tufts University and the University of Liverpool.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hidehiro Takei, MD 6431 Fannin Street, Msb 2.136, Houston, TX 77030-1501 Ph: (713) 500-5301 | Hidehiro Takei, MD 6411 Fannin Street, Houston, TX 77030-1501 Ph: (713) 704-4000 |
News Archive
Boehringer Ingelheim will present results from LUX-Lung 3, the company's pivotal Phase III clinical trial investigating afatinib in patients with stage IIIB or IV non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) mutation (EGFR M+), at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2012.
Findings from a large-scale clinical trial testing a new palliative care model have shown to be lower cost, viewed positively by patients and their carers while showing no difference in patient-reported outcomes when compared with standard care.
The bipartisan treatment the FDA user fee bill has enjoyed did not fall like manna from heaven. It came at the insistence of the pharmaceutical and medical device industries, the FDA and legislators on both sides of the aisle who agreed early on they would get a deal done. And then actually did it.
The Cancer Council Australia cautioned that the vaccine was not a substitute for the Pap screen and that all women aged 18-69 should continue regular two year screening.
The Food and Drug Administration's mandatory added sugar labeling policy for packaged foods and beverages, set to take effect between 2020 and 2021, could be a cost-effective way to generate important health gains and cost-savings for both the healthcare system and society in the U.S., according to a new modeling study led by researchers from the Friedman School of Nutrition Science and Policy at Tufts University and the University of Liverpool.
› Verified 3 days ago
Dr. Angshumoy Roy, M.D., PH.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1 Baylor Plz, Pathology, Baylor College Of Medicine, Houston, TX 77030 Phone: 713-873-3224 | |
Dr. Bryan Keith Guillory, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 713-792-6161 | |
Dr. Ross A Miller, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 6565 Fannin Street, Suite B490, Houston, TX 77030 Phone: 713-441-9027 Fax: 713-793-1603 | |
Dr. Richard Hausner, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 10655 Steepletop Dr, Pathology Department, Houston, TX 77065 Phone: 281-897-3165 Fax: 281-897-0170 | |
Darshan R Phatak, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1885 Old Spanish Trail, Harris County Medical Examiner, Houston, TX 77054 Phone: 713-796-6776 | |
Dr. Choladda Vejabhuti Curry, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 6621 Fannin St, Ab1195, Houston, TX 77030 Phone: 832-824-5161 Fax: 832-825-1032 | |
Zhonghua Liu, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1515 Holcombe Blvd, Houston, TX 77030 Phone: 832-785-9142 |